Staying on top of insulin delivery systems is one of the most practical ways to improve daily life with diabetes. In 2025 the conversation is no longer just “pump or pens.” It is about smarter automation, tubeless wearables, connected pen caps, patch devices for mealtime dosing, and once-weekly options emerging in some regions. If you are chasing better time in range, fewer alarms, and less decision fatigue, this year’s diabetes innovation wave brings real choices that can fit your lifestyle and budget. The guide below breaks down what is new, what has changed, and what to ask your care team before you switch.
The 2025 picture at a glance
Automated insulin delivery systems that pair a pump with a continuous glucose monitor and an algorithm are now mainstream, with the American Diabetes Association’s 2025 Standards of Care underscoring their role in improving outcomes. The same document expands guidance on device access and early device selection, signaling that technology is central to modern insulin therapy, not an optional add-on.
At the same time, innovation is not limited to pumps. Smart pens and pen caps help people on injections get dose calculators, reminders, and CGM-powered insights without moving to a pump. Wearable patches are filling the gap for mealtime insulin or all-day basal needs, and infusion sets are stretching from 2 to 3 days out to a full week on approved systems.
Wearable insulin pumps: the biggest updates to watch
Omnipod 5 gets broader and smarter
Insulet’s Omnipod 5 remains the only tubeless automated system in the U.S. and now works with the Dexcom G7. In 2024 the FDA expanded Omnidpod 5’s indication to adults with type 2 diabetes, which opens a simple path to automation for many who previously relied on multiple daily injections. If you prefer to avoid tubing and want algorithm-guided corrections with CGM data, this one is high on the shortlist.
Tandem Mobi and Control-IQ+ focus on discretion and phone control
Tandem’s pocket-sized Mobi pump brought full smartphone control to a commercial AID system, and in March 2025 the company launched Control-IQ+, an updated algorithm designed to refine automatic correction dosing. For people who value an unobtrusive pump with app control, Mobi is compelling. Tandem also secured FDA clearance for a 7-day infusion set in August 2025, with commercial timing expected in 2026, which should cut site changes roughly in half once available.
Medtronic MiniMed 780G levels up hardware and indications
Medtronic’s MiniMed 780G advanced hybrid closed loop continues to add capabilities. The company’s Simplera Sync next-gen CGM is designed to work with 780G, and in September 2025 Medtronic announced U.S. clearance expanding 780G to people with type 2 diabetes. Medtronic also offers the Extended infusion set and reservoir, indicated for up to 7 days of wear on compatible pumps, reducing set changes and supply waste for many users.
iLet Bionic Pancreas emphasizes simplicity
The iLet Bionic Pancreas from Beta Bionics aims to remove the burden of carb counting by using a fully automated algorithm that adapts dosing in the background. The system works with integrated CGMs, including Dexcom G7 and Abbott’s Libre 3 Plus in supported configurations. If you want the least amount of daily math, iLet is worth a careful look, though availability and compatible sensors may vary by market and timing.
Smart pens and connected caps: powerful upgrades for MDI
InPen by Medtronic
InPen is a reusable smart insulin pen that pairs with a mobile app to track doses, calculate mealtime and correction doses, and integrate CGM data. As of 2025, InPen is compatible with Dexcom G6 and G7, though visualization of CGM data inside the app can have a brief delay. For people on injections who want pump-style decision support, InPen is one of the most mature options available in the U.S.
Lilly Tempo Smart Button and platform
Lilly’s Tempo ecosystem combines a compatible pen, the Tempo Smart Button, and the TempoSmart app to capture insulin doses and provide coaching features. It emphasizes reminders, digital logbooks, and data sharing with your clinical team. Tempo is prescription-only and designed to work with Lilly’s insulins within the platform.
Bigfoot Unity for CGM-guided dosing
The Bigfoot Unity system uses connected pen caps that read data from Abbott’s Libre sensors to suggest correction doses based on clinician-set parameters. Cleveland Clinic’s clinical primer highlights the workflow and integration with Libre 2, and 2025 conference coverage reported sustained glycemic improvements and reduced diabetes distress over 12 months in Unity users. If you like the idea of seeing dose suggestions right on the pen cap, Unity can streamline your routine.
Patch devices and basal-only options
CeQur Simplicity for mealtime insulin
CeQur Simplicity is a wearable, mechanical patch that delivers rapid-acting insulin for mealtime and correction boluses. The device now has FDA clearance for up to 4 days of wear, holds up to 200 units, and is single-use. It can be an attractive option if you want to eliminate most injections without committing to a full pump.
V-Go for basal plus bolus coverage
V-Go is a disposable, 24-hour wearable that provides a preset basal rate along with on-demand mealtime dosing via a simple button. The device is available in multiple fixed basal rates and is now part of MannKind’s portfolio in the U.S. For some adults with type 2 diabetes, V-Go delivers meaningful A1C reductions with less total insulin than multiple daily injections.
Omnipod GO as a basal-only pod
Omnipod GO is a basal-only, 72-hour wearable cleared for adults with type 2 diabetes. It provides a fixed rate of rapid-acting insulin, offering a simple alternative to daily long-acting injections. If you want the feel of a pod without the complexity of a full AID system, GO is designed for that niche.
Algorithm-only apps and interoperability to watch
CamDiab’s CamAPS FX received FDA clearance in 2024 as a mobile app that can control compatible pumps and work with integrated CGMs. Internationally, CamAPS FX already powers the mylife Loop with Ypsomed’s YpsoPump and supports Libre 3 and Dexcom G6 in various regions. In the U.S., the app is cleared, but widespread use awaits compatible pump availability and integrations, so timelines may vary.
Longer wear, fewer hassles: 7-day infusion sets
Set changes create friction, so extended-wear technology matters. Medtronic’s Extended infusion set and reservoir are indicated for up to 7 days on compatible pumps, and early real-world data suggest fewer changes with maintained glycemic outcomes. Tandem received FDA clearance for its own 7-day SteadiSet infusion set in August 2025, with commercial rollout expected in 2026. If site changes are your main pain point, these advances are worth asking about.
What about once-weekly insulin?
Insulin icodec, a once-weekly basal insulin, is approved in multiple regions including the EU, Canada, Japan, Australia, and Switzerland, but as of September 2025 it is not approved in the United States following the FDA’s 2024 complete response letter. If you travel or live abroad, you may hear about it under the brand name Awiqli. In the U.S., keep in touch with your clinician for updates on the regulatory path.
Choosing the right insulin delivery system in 2025
Real-world fit often matters more than feature lists. Think about where and how you wear devices, your phone ecosystem, your insulin needs, and your insurance channel. Some systems ship through the pharmacy benefit, others through durable medical equipment, and a few can do both. If you are new to automation, a tubeless wearable can reduce the learning curve. If you are happy on injections but want stronger decision support, a smart pen or cap can bring many pump-like benefits without a major lifestyle change.
Five questions to take to your care team
- How will this system change my time in range and hypoglycemia risk based on my current data
- What sensors and phones are compatible today, not just “coming soon”
- How often do I change pods, sets, or patches, and what is the monthly supply count
- Is my plan’s coverage pharmacy or DME, and what are my expected out-of-pocket costs
- If the app or sensor goes down, what is my backup plan for dosing and monitoring
Safety, privacy, and updates
Connected devices rely on secure software and reliable wireless links. Keep your apps updated, review data-sharing settings, and discuss backup plans with your clinician in case of outages. Academic reviews in 2025 highlight both the promise of AI-driven dosing and the importance of cybersecurity and standardized safety checks. Treat your system like any other critical medical device, and do not skip training.
Bottom line for 2025
The best insulin delivery systems in 2025 share three traits: they lighten your daily mental load, integrate cleanly with CGM data, and give you flexibility to live the way you want. Whether that is a tubeless automated pump, a small phone-controlled pump, a smart pen with clear dose advice, or a simple patch for mealtime insulin, there is likely a setup that fits your goals and routine. Use your time in range, hypoglycemia patterns, device comfort, and budget to guide the choice.
Where to get trusted supplies and guidance
If you are ready to compare pumps, infusion sets, CGMs, smart pens, or patch supplies, reach out to Smiles Medical Supply for help selecting components that match your prescription, coverage, and day-to-day needs. Their team can walk you through current options and get you set up with the right products and refills so you can focus on your life, not logistics.
